Vaccine adjuvant ARNAX promotes mucosal IgA production in influenza HA vaccination.

Related Articles

Vaccine adjuvant ARNAX promotes mucosal IgA production in influenza HA vaccination.

Biochem Biophys Res Commun. 2018 Nov 04;:

Authors: Takeda Y, Takaki H, Fukui-Miyazaki A, Yoshida S, Matsumoto M, Seya T

Abstract
Adjuvant stimulates pattern-recognition receptors (PRRs) expressed by dendritic cells, which causes immune-enhancing of T lymphocytes. Adjuvant also induces innate immune response in whole-body cells via PRRs to evoke cytokinemia. A cytokine-mediated immune response is important for the systemic protection of a host from microbial infections. Using an influenza subcomponent vaccine in a mouse model, we intranasally administered a TLR3-specific adjuvant ARNAX + HA split vaccine to mice. ARNAX efficiently induced mucosal IgA and systemic IgG production by nasal drop. Moreover, ARNAX + HA simultaneously induced CD8 and CD4 T cell activation. We have previously shown that ARNAX does not induce harmful systemic cytokine production. Thus, our findings indicate that the ARNAX + HA vaccine is a harmless prophylactic vaccine for flu that induces HA-specific T cell activation and IgA/IgG production. These results suggested that ARNAX + antigen enhanced the immune response without inducing inflammatory toxicity for vaccination against infectious diseases.

PMID: 30404733 [PubMed - as supplied by publisher]

https://ift.tt/2z2Oufv